Zhende Medical Co., Ltd. (SHA:603301)
China · Delayed Price · Currency is CNY 81.73
+0.49 (0.60%)
Sep 14, 2026, 3:00 PM CST
Zhende Medical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 21,556 | 18,732 | 5,856 | 6,477 | 10,059 | 11,564 | |
Market Cap Growth | 174.84% | 219.86% | -9.58% | -35.61% | -13.02% | -14.29% |
Enterprise Value | 22,188 | 19,341 | 5,978 | 5,723 | 9,327 | 10,827 |
Last Close Price | 81.73 | 70.26 | 21.23 | 23.10 | 34.04 | 45.21 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 77.79 | 71.82 | 15.21 | 32.64 | 14.80 | 19.41 |
Forward PE | 43.94 | 42.34 | 12.67 | 9.13 | 11.70 | 18.82 |
PS Ratio | 4.84 | 4.33 | 1.37 | 1.57 | 1.64 | 2.27 |
PB Ratio | 3.63 | 3.14 | 0.99 | 1.16 | 1.75 | 2.61 |
P/TBV Ratio | 5.46 | 4.77 | 1.41 | 1.63 | 2.23 | 3.59 |
P/FCF Ratio | 586.36 | - | - | - | 20.45 | 94.66 |
P/OCF Ratio | 51.00 | 34.79 | 12.70 | 14.33 | 8.07 | 14.14 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.98 | 4.47 | 1.40 | 1.39 | 1.52 | 2.13 |
EV/EBITDA Ratio | 33.15 | 31.50 | 9.62 | 12.02 | 9.34 | 12.61 |
EV/EBIT Ratio | 63.44 | 59.31 | 15.94 | 24.53 | 11.47 | 14.89 |
EV/FCF Ratio | 603.54 | - | - | - | 18.96 | 88.62 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.22 | 0.22 | 0.10 | 0.11 | 0.11 | 0.19 |
Debt / EBITDA Ratio | 1.98 | 2.07 | 0.95 | 1.34 | 0.60 | 0.98 |
Debt / FCF Ratio | 36.13 | - | - | - | 1.23 | 6.94 |
Net Debt / Equity Ratio | 0.06 | 0.03 | -0.04 | -0.10 | -0.27 | -0.12 |
Net Debt / EBITDA Ratio | 0.56 | 0.28 | -0.39 | -1.20 | -1.57 | -0.60 |
Net Debt / FCF Ratio | 10.00 | -14.80 | 0.78 | 3.88 | -3.19 | -4.22 |
Asset Turnover | 0.53 | 0.54 | 0.57 | 0.54 | 0.86 | 0.79 |
Inventory Turnover | 3.58 | 3.80 | 3.63 | 3.30 | 4.61 | 3.51 |
Quick Ratio | 1.02 | 1.04 | 1.50 | 1.54 | 1.98 | 1.31 |
Current Ratio | 1.66 | 1.58 | 2.28 | 2.32 | 2.72 | 1.99 |
Return on Equity (ROE) | 4.85% | 4.50% | 6.91% | 3.76% | 13.77% | 16.19% |
Return on Assets (ROA) | 2.61% | 2.55% | 3.16% | 1.92% | 7.10% | 7.09% |
Return on Invested Capital (ROIC) | 4.72% | 4.55% | 5.86% | 4.93% | 17.54% | 19.57% |
Return on Capital Employed (ROCE) | 5.30% | 4.90% | 5.80% | 3.80% | 12.70% | 15.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.28% | 1.39% | 6.58% | 3.06% | 6.76% | 5.15% |
FCF Yield | 0.17% | -0.06% | -5.27% | -2.27% | 4.89% | 1.06% |
Dividend Yield | 0.37% | 0.43% | 3.06% | 5.41% | - | 1.33% |
Payout Ratio | 41.08% | 77.25% | 41.38% | 213.57% | 24.16% | 91.24% |
Buyback Yield / Dilution | 0.37% | 0.82% | 0.92% | -13.18% | -4.56% | -11.08% |
Total Shareholder Return | 0.74% | 1.25% | 3.98% | -7.77% | -4.56% | -9.76% |